KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Non-Current Liabilities (2016 - 2025)

Jazz Pharmaceuticals has reported Total Non-Current Liabilities over the past 15 years, most recently at $7.2 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $7.2 billion for Q4 2025, down 7.86% from a year ago — trailing twelve months through Dec 2025 was $7.2 billion (down 7.86% YoY), and the annual figure for FY2025 was $7.2 billion, down 7.86%.
  • Total Non-Current Liabilities for Q4 2025 was $7.2 billion at Jazz Pharmaceuticals, down from $7.3 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for JAZZ hit a ceiling of $8.9 billion in Q2 2021 and a floor of $2.9 billion in Q1 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $7.6 billion (2023), compared with a mean of $7.5 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 220.77% in 2021 and later decreased 12.06% in 2022.
  • Jazz Pharmaceuticals' Total Non-Current Liabilities stood at $8.2 billion in 2021, then decreased by 7.2% to $7.6 billion in 2022, then decreased by 0.95% to $7.5 billion in 2023, then rose by 3.96% to $7.8 billion in 2024, then fell by 7.86% to $7.2 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $7.2 billion (Q4 2025), $7.3 billion (Q3 2025), and $7.1 billion (Q2 2025) per Business Quant data.